Former Legend Biotech chief Ying Huang named CEO of K2, targets $250 million Series A to license Asian assets

Ying Huang spent the past seven years building one of the leading cancer cell‑therapy companies before stepping down as CEO of Legend Biotech.

Weeks after announcing his departure, Huang has taken the helm as chief executive of K2, a new biotech startup.

K2’s strategy includes raising a $250 million Series A round to fund the licensing of Asian assets for its pipeline.

The move signals Huang’s shift from leading an established cell‑therapy player to driving growth at an early‑stage company.